United States
Healthcare-focused private equity, lending and finance conference will explore ways to successfully close transactions and achieve growth.
Department issued compliance alert explains the sales and use tax collection responsibilities for marketplace facilitators and sellers.
The shift toward highly customized products and services will serve as a growth catalyst for the life sciences industry.
Three states have prescriptions for opioid taxes on manufacturers and distributors. Here’s what you need to know.
RSM implemented the ERP system and managed the integration of the finance and accounting outsourcing technology stack.
A white paper about how entities in the life sciences industry may be affected by the new revenue recognition guidance in ASC 606.
Notwithstanding unfavorable changes to the Code, capital gain treatment is still available on the sale of patents in certain scenarios.
From funding to financing, venture capital activity through the third quarter of 2019 has been record breaking.
From contract research organizations to initial public offerings, life sciences finance leaders discuss issues in the bioscience businesses.
RSM senior industry analyst Adam Lohr shares the latest on deals, going public and more in the biotech, pharma and medical devices sectors.
What’s the secret to successful supply chain outsourcing in your life sciences business? Learn how technology can make the difference.
Syneos Health, a public company, shares its ASC 842 implementation journey and how RSM assisted with acting as an extension of their team.
Get yourself up to speed on the latest trends in private equity and mergers and acquisitions with the Q3 2019 HC and LS Industry Spotlight.
Pharmaceutical, biotech and medical device company finance leaders discuss ASC 842 lease accounting adoption complexities and challenges.
What can life sciences businesses do to ensure data protection, especially with their third parties? Get key cybersecurity considerations.
Get yourself up to speed on the latest trends in private equity and mergers and acquisitions with the Q2 2019 HC and LS Industry Spotlight.
Skepticism regarding artificial intelligence is understandable, but it’s often based on a misunderstanding of what AI really is.
How can life sciences companies looking to go public position themselves for success? It’s all about setting the stage early on.
Get yourself up to speed on the latest trends in private equity and mergers and acquisitions with the Q1 2019 HC and LS Industry Spotlight.
Patient support programs can become a risk to life sciences product manufacturers if used to gain preferential treatment for their products.